Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it was concluded GSK will submit local PSURs
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This PMS study aims to collect safety and reactogenicity data of Cervarix in the local population as per the licensing requirement of the Sri Lankan regulatory authority.
Subjects who received one or two doses of Cervarix prior to the start of this PMS study can also be enrolled in the study. These subjects would receive either 2 doses or 1 dose respectively after being enrolled in the study.
Since there is lack of clarity regarding the PMS study requirement (both from Regulatory agency and Ethics Committee), it was decided that GSK will submit Local PSURs on a regular basis as desired by Local regulatory agency. The same is communicated to Regulatory agency and if they want something more they are requested to revert back with specific requirements.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort Group | Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cervarix data collection | Other | Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of solicited local adverse events (AEs). | During the 7-day period (Days 0-6) following any dose of Cervarix and overall. | |
| Occurrence of solicited general AEs. | During the 7-day period (Days 0-6) following any dose of Cervarix and overall. | |
| Occurrence of unsolicited AEs. | During the 30-day period (Days 0-29) following any dose of Cervarix and overall. | |
| Occurrence of any Serious adverse events (SAEs) and SAE(s) causally related to vaccination. | Throughout the PMS study period (up to six months after the last dose of Cervarix). | |
| Occurrence of potential Immune-Mediated Diseases (pIMDs). | Throughout the PMS study period (up to six months after the last dose of Cervarix). | |
| Occurrence of Medically Significant Condition (MSCs). | Throughout the PMS study period (up to six months after the last dose of Cervarix). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Healthy females aged 10 years and above who will receive Cervarix as a part of routine practice as per the PI in Sri Lanka.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
Not provided
| ID | Term |
|---|---|
| D030361 | Papillomavirus Infections |
| ID | Term |
|---|---|
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D003625 | Data Collection |
| ID | Term |
|---|---|
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
| Data Collection | Other | All adverse events will be recorded by diary card, follow-up visit or telephone contact. |
|
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D014412 | Tumor Virus Infections |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |